GlobeNewswire·Jun 1, 2026, 9:00 AM ET

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

DRTS DRTSW

Alpha Tau Medical presented pooled analysis of three Phase I/II trials at the 2026 ASCO Annual Meeting, demonstrating Alpha DaRT feasibility & safety as a one-time minimally invasive intratumoral treatment for pancreatic ductal adenocarcinoma (PDAC).
Patients receiving Alpha DaRT after first-line chemotherapy achieved median overall survival (mOS) of 11.2 months (metastatic) & 11.1 months (locally advanced), significantly exceeding historical benchmarks of ~4-6 months & ~9 months respectively for second-line chemotherapy.
Second-line Alpha DaRT treatment yielded mOS of 17.0 months (metastatic) & 13.8 months (locally advanced) from prior chemotherapy initiation, while heavily pretreated third-line patients achieved mOS of 17.1 months (locally advanced) & 11.3 months (metastatic).
Alpha DaRT-treated patients with no prior chemotherapy showed mOS of 7.1 months from diagnosis, including 6.3 months (locally advanced) & 5.8 months (metastatic) from trial enrollment.
Safety data revealed a favorable profile with treatment-associated adverse events in 36% of subjects, Grade ≥3 events in 9%, no treatment-related deaths, full resolution of Grade ≥3 events, & no chronic toxicity.
Alpha Tau plans to complete recruitment in the U.S. IMPACT trial, which evaluates Alpha DaRT combined with front-line chemotherapy to deliver potent local dosing without exacerbating systemic side effects.
Additional trials include the ACAPELLA study in France combining Alpha DaRT with capecitabine & a new percutaneous delivery approach at the University of Verona to broaden patient accessibility.
The pooled analysis combined data from studies at the Jewish General Hospital, Centre Hospitalier de l'Université de Montréal, & Hadassah Medical Center, analyzing survival via the Kaplan-Meier method across varying chemotherapy lines.